EP1658034A4 - Antibiotic product, use and formulation thereof - Google Patents

Antibiotic product, use and formulation thereof

Info

Publication number
EP1658034A4
EP1658034A4 EP20040781957 EP04781957A EP1658034A4 EP 1658034 A4 EP1658034 A4 EP 1658034A4 EP 20040781957 EP20040781957 EP 20040781957 EP 04781957 A EP04781957 A EP 04781957A EP 1658034 A4 EP1658034 A4 EP 1658034A4
Authority
EP
Grant status
Application
Patent type
Prior art keywords
formulation
use
antibiotic product
antibiotic
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20040781957
Other languages
German (de)
French (fr)
Other versions
EP1658034A2 (en )
Inventor
Beth A Burnside
Henry H Flanner
Colin Rowlings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi Inc
Original Assignee
Middlebrook Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
EP20040781957 2003-08-29 2004-08-20 Antibiotic product, use and formulation thereof Withdrawn EP1658034A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US49882903 true 2003-08-29 2003-08-29
PCT/US2004/027369 WO2005023184A3 (en) 2003-08-29 2004-08-20 Antibiotic product, use and formulation thereof

Publications (2)

Publication Number Publication Date
EP1658034A2 true EP1658034A2 (en) 2006-05-24
EP1658034A4 true true EP1658034A4 (en) 2011-06-22

Family

ID=34272735

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20040781957 Withdrawn EP1658034A4 (en) 2003-08-29 2004-08-20 Antibiotic product, use and formulation thereof

Country Status (5)

Country Link
US (1) US8246996B2 (en)
EP (1) EP1658034A4 (en)
JP (1) JP5686494B2 (en)
CA (1) CA2535780A1 (en)
WO (1) WO2005023184A3 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
EP1945189A4 (en) * 2005-11-03 2012-08-15 Sun Pharmaceutical Ind Ltd Coated tablets having prolonged gastric retention

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062229A1 (en) * 2000-02-24 2001-08-30 Advanced Pharma, Inc. Therapeutic product, use and formulation thereof
WO2004012704A1 (en) * 2002-08-02 2004-02-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2004103311A2 (en) * 2003-05-19 2004-12-02 Advancis Pharmaceuticals Corporation Antibiotic composition

Family Cites Families (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108046A (en) * 1960-11-25 1963-10-22 Smith Kline French Lab Method of preparing high dosage sustained release tablet and product of this method
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4175125A (en) * 1971-12-27 1979-11-20 Eli Lilly And Company Method for treating methicillin resistant staphylococcus aureus
US4131672A (en) 1975-06-09 1978-12-26 Eli Lilly And Company Method for treating methicillin resistant Staphylococcus aureus
GB1472534A (en) * 1973-07-06 1977-05-04 Glaxo Lab Ltd 7beta-hydroxyiminoacylamido-cephalosporins
US4018918A (en) * 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
US4529720A (en) 1974-04-20 1985-07-16 Beecham Group, P.L.C. Antibiotic from Streptomyces clavulicerus
FR2267778B1 (en) 1974-04-20 1978-11-17 Beecham Group Ltd
JPS5760346B2 (en) * 1974-08-09 1982-12-18 Takeda Chemical Industries Ltd
US4048306A (en) * 1975-04-07 1977-09-13 Boehringer Ingelheim Gmbh Aldehyde-erythromycylamine condensation products
US6031093C1 (en) * 1975-04-17 2001-10-16 Smithkline Beecham Plc Solid salts of clavulanic acid
US6218380B1 (en) 1975-04-17 2001-04-17 Smithkline Beecham P.L.C. Pharmaceutical compositions
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
US4236211A (en) * 1978-09-15 1980-11-25 Pfizer Inc. Method and apparatus for determining the minimum concentration of antibiotic necessary to at least inhibit microorganism growth
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
FR2470599B1 (en) * 1979-12-07 1983-03-25 Panoz Donald
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4399151A (en) * 1980-06-16 1983-08-16 Merrell Dow Pharmaceuticals Inc. Method of inhibiting the growth of protozoa
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
GB2114969B (en) 1980-10-31 1985-02-20 Leo Pharm Prod Ltd Penicillins
EP0052075A1 (en) 1980-11-12 1982-05-19 Ciba-Geigy Ag Sustained release pharmaceutical granule
US4517359A (en) 1981-03-06 1985-05-14 Sour Pliva Farmaceutska, Kemijska Prehrambena I Kozmeticka Industrija, N.Sol.O. 11-Methyl-11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one and derivatives thereof
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4435173A (en) * 1982-03-05 1984-03-06 Delta Medical Industries Variable rate syringe pump for insulin delivery
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4598045A (en) 1982-08-25 1986-07-01 Hana Biologics, Inc. Triphasic mycoplasmatales detection method
US4430495A (en) * 1982-09-17 1984-02-07 The Upjohn Company Process for preparing lincomycin and clindamycin ribonucleotides
JPS6232166B2 (en) * 1983-06-15 1987-07-13 Shionogi & Co
CA1272713C (en) * 1983-10-04 1990-08-14
DE3405378A1 (en) * 1984-02-15 1985-08-22 Roehm Gmbh Arzneimittelueberzug
JPH053475B2 (en) 1984-04-06 1993-01-14 Taisho Pharma Co Ltd
US4616008A (en) * 1984-05-02 1986-10-07 Takeda Chemical Industries, Ltd. Antibacterial solid composition for oral administration
US4568741A (en) * 1984-05-15 1986-02-04 The Upjohn Company Synthesis of 7-halo-7-deoxylincomycins
US4879135A (en) * 1984-07-23 1989-11-07 University Of Medicine And Dentistry Of New Jersey Drug bonded prosthesis and process for producing same
JPH053476B2 (en) 1984-10-26 1993-01-14 Taisho Pharma Co Ltd
US4710565A (en) 1984-11-29 1987-12-01 The Upjohn Company Thesis of 7-halo-7-deoxylincomycins
DE3583799D1 (en) 1985-01-11 1991-09-19 Abbott Lab Ltd Solid preparation with slow release.
JPS61210025A (en) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk Stabilized antibioitc complex granule preparation
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4894119A (en) * 1985-04-10 1990-01-16 Drew Chemical Corporation Retention and/or drainage and/or dewatering aid
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4775751A (en) * 1985-06-03 1988-10-04 Eli Lilly & Company Process for cephalexin hydrochloride alcoholates
DE3524572A1 (en) 1985-07-10 1987-01-15 Thomae Gmbh Dr K Solid pharmaceutical preparations for oral application containing 9-deoxo-11-deoxy-9,11- (imino (2- (2-methoxyethoxy) ethylidene) oxy) - (9S) -erythromycin, and processes for their preparation
DE3684446D1 (en) * 1985-12-28 1992-04-23 Sumitomo Pharma Drugs with delayed shock wise release.
US4723958A (en) * 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
NL193136C (en) * 1986-07-02 1998-12-04 Shionogi & Co Crystalline hydrate of an oral cephalosporin derivative, process for the preparation thereof, and pharmaceutical product therefrom.
KR960000434B1 (en) * 1986-12-17 1996-01-06 우에하라 쇼지 Eryhromycin a derivatives and process of method for the same
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
JPS63162619A (en) * 1986-12-25 1988-07-06 Teisan Seiyaku Kk Delayed soluble granule and sustained release complex granule using said granule
US4749568A (en) 1987-01-23 1988-06-07 The Upjohn Company Rubradirin treatment of methicillin-resistant staph
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US4945405A (en) 1987-05-21 1990-07-31 Minolta Camera Kabushiki Kaisha Color image read apparatus with shading and color balance correction
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
US4945080A (en) 1987-05-26 1990-07-31 Eli Lilly And Company Dirithromycin metabolite
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4835140A (en) 1987-08-20 1989-05-30 Indiana University Foundation Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine
US4915953A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering acetaminophen or phenylpropanolamine
LU87041A1 (en) * 1987-11-04 1989-06-14 Oreal Retinoic esters of macrolides and their method of preparing pharmaceutical compositions and cosmetics containing them
JP2751385B2 (en) 1988-05-19 1998-05-18 大正製薬株式会社 Method for producing erythromycin a oxime and its salts
US4895934A (en) * 1988-08-22 1990-01-23 E. I. Du Pont De Nemours And Company Process for the preparation of clindamycin phosphate
US4849515A (en) 1988-08-22 1989-07-18 E. I. Du Pont De Nemours And Company Clindamycin-2-phosphoryl benzylate
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5110598A (en) 1989-06-30 1992-05-05 Smithkline Beecham Corp. Intermittent release dosage form
US5178874A (en) * 1989-06-30 1993-01-12 Smithkline Beechman Corporation Intermittent release dosage form
DK0418565T3 (en) 1989-09-21 1995-01-23 American Cyanamid Co Pulsed delivery system minocycline once daily
DK469989D0 (en) 1989-09-22 1989-09-22 Bukh Meditec pharmaceutical preparation
US5204055A (en) * 1989-12-08 1993-04-20 Massachusetts Institute Of Technology Three-dimensional printing techniques
US5387380A (en) * 1989-12-08 1995-02-07 Massachusetts Institute Of Technology Three-dimensional printing techniques
JPH0674206B2 (en) 1989-12-28 1994-09-21 田辺製薬株式会社 Controlled release formulations and their preparation
US5229131A (en) 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5358713A (en) * 1990-02-23 1994-10-25 Mitsui Norin Co., Ltd. Method of preventing the transmission of infection caused by methicillin-resistant Staphylococcus aureus
US5182374A (en) * 1990-03-21 1993-01-26 American Cyanamid Company Clindamycin phosphate synthesis
GB9103795D0 (en) * 1991-02-22 1991-04-10 Evans Brian K Delayed release oral dosage forms for treatment of intestinal disorders
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
EP0535900B1 (en) * 1991-09-30 1996-01-17 Eli Lilly And Company One step process for production of dirithromycin
US5334590A (en) * 1991-10-17 1994-08-02 Merck & Co., Inc. MRSA active 2-phenyl-carbapenems
US5476854A (en) 1991-11-27 1995-12-19 Sepracor Inc. Methods and compositions for treating bacterial infection using optically pure (R)-lomefloxacin
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5422343A (en) 1992-12-21 1995-06-06 Otsuka Pharmaceutical Factory, Inc. Prophylactic and therapeutic composition for MRSA infection
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US6117843A (en) * 1992-02-18 2000-09-12 Lloyd J. Baroody Compositions for the treatment of acne containing clindamycin and benzoyl peroxide
JPH07504168A (en) * 1992-02-18 1995-05-11
JP3265680B2 (en) * 1992-03-12 2002-03-11 大正製薬株式会社 Oral pharmaceutical compositions
US5230703A (en) 1992-04-09 1993-07-27 Staodyn, Inc. Wound infection resolution utilizing antibiotic agents and electrical stimulation
CA2134467A1 (en) * 1992-04-30 1993-11-11 Donald Johnson Stable hydrated cephalosporin dry powder for oral suspension formulation
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
EP0582396B1 (en) 1992-07-30 2001-01-03 Pfizer Inc. Taste-masking composition of bitter pharmaceutical agents
CN1078074C (en) * 1992-07-31 2002-01-23 尼奥斯药品公司 Composition for treating and inhibiting gastric and duodenal ulcers
US6183778B1 (en) * 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
US5688516A (en) * 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
JP3319800B2 (en) * 1993-02-01 2002-09-03 辻本化学工業株式会社 Anti-resistant Staphylococcus aureus compound
US5414014A (en) 1993-04-08 1995-05-09 Innova Biomed, Inc. Methods for efficacious removal of attached, sucking antropods from human dermis
EP0804174A4 (en) * 1993-07-21 1998-09-09 Univ Kentucky Res Found A multicompartment hard capsule with control release properties
CA2161538A1 (en) * 1993-07-22 1995-02-02 S. Shirley Yang Controlled release tacrine drug delivery systems and methods for preparing same
CA2101241C (en) 1993-07-23 1998-12-22 Jonathan P. Wong Liposome-encapsulated ciprofloxacin
US6020002A (en) 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US5518680A (en) 1993-10-18 1996-05-21 Massachusetts Institute Of Technology Tissue regeneration matrices by solid free form fabrication techniques
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US6063613A (en) 1993-12-06 2000-05-16 The Rockefeller University Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof
US6251647B1 (en) 1993-12-06 2001-06-26 The Rockefeller University Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
DE4404018A1 (en) * 1994-02-09 1995-08-10 Merck Patent Gmbh Protracted release dosage forms containing clindamycin palmitate
US5466446A (en) * 1994-02-16 1995-11-14 Stiefel Laboratories, Inc. Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
JPH09511738A (en) * 1994-04-01 1997-11-25 マイクロサイド・ファーマシューティカルズ・インコーポレーテッド Cephalosporin antibiotic
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
US5856474A (en) 1994-04-25 1999-01-05 Biochemie Gesellschaft, M.B.H. Cephalosporin synthesis
RU2130311C1 (en) 1994-05-06 1999-05-20 Пфайзер Инк. Medicinal controlled-releasing forms of azithromycin
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
FR2722098B1 (en) 1994-07-06 1996-08-23 Cird Galderma New medicines at basic metronidazole or a synergistic mixture of metronidazole and clindamycin
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
US5702895A (en) 1995-01-19 1997-12-30 Wakunaga Seiyaku Kabushiki Kaisha Method and kit for detecting methicillin-resistant Staphylococcus aureus
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
DE69636864D1 (en) * 1995-05-02 2007-03-15 Taisho Pharma Co Ltd Agents for oral administration
US5755753A (en) 1995-05-05 1998-05-26 Thermage, Inc. Method for controlled contraction of collagen tissue
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6136587A (en) * 1995-07-10 2000-10-24 The Rockefeller University Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof
US6013507A (en) * 1995-07-10 2000-01-11 The Rockefeller University Auxiliary genes and proteins of methicillin resistant bacteria and antagonists thereof
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US5780058A (en) 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US5919489A (en) 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5872229A (en) * 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5998194A (en) 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
CN1142792C (en) * 1996-01-08 2004-03-24 阿斯特拉曾尼卡有限公司 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
WO1997029765A1 (en) 1996-02-16 1997-08-21 The Regents Of The University Of California Antimicrobial peptides and methods of use
JP3957338B2 (en) 1996-02-23 2007-08-15 啓一 平松 Diagnostics
US5766220A (en) * 1996-02-29 1998-06-16 Moenning; Stephen P. Apparatus and method for protecting a port site opening in the wall of a body cavity
US5951588A (en) 1996-02-29 1999-09-14 Moenning; Stephen P. Apparatus and method for protecting a port site opening in the wall of a body cavity
EP0896526A1 (en) * 1996-03-13 1999-02-17 Biochemie Gesellschaft M.B.H. Agglomerates containing beta-lactam compounds
US5837829A (en) * 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) * 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5808017A (en) * 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
US5719132A (en) 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US5780446A (en) 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
US5985643A (en) 1996-07-10 1999-11-16 The Rockefeller University Auxiliary gene and protein of methicillin resistant bacteria and antagonists thereof
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5844105A (en) 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
GB9617780D0 (en) 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
CA2266404A1 (en) * 1996-09-17 1998-03-26 Amur Pharmaceuticals, Inc. Phospholipid drug derivatives
EP0941064B1 (en) 1996-11-17 2006-01-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED RELEASE OF beta -LACTAM ANTIBIOTICS
US5840760A (en) * 1996-11-19 1998-11-24 Florida Atlantic University materials and methods for controlling methicillin-resistant Staphylococcus aureus microbes
US6027748A (en) * 1997-01-08 2000-02-22 Jagotec Ag Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
US5980942A (en) 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US5864023A (en) * 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US6280771B1 (en) * 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
DE19718012C1 (en) * 1997-04-29 1998-10-08 Jenapharm Gmbh A process for the preparation of perorally administered solid drug with controlled effective ingredient delivery
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US5877243A (en) * 1997-05-05 1999-03-02 Icet, Inc. Encrustation and bacterial resistant coatings for medical applications
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2248908T7 (en) * 1997-06-06 2014-11-24 Depomed, Inc. Dosage forms of drugs orally and gastric retention for sustained release of drugs highly soluble
WO1999000136A1 (en) * 1997-06-27 1999-01-07 The University Of New England Control of acidic gut syndrome
US6503709B1 (en) * 1997-07-03 2003-01-07 Id Biomedical Corporation Methods for rapidly detecting methicillin resistant staphylococci
US6265394B1 (en) 1997-07-31 2001-07-24 Bristol-Myers Squibb Company Bis quaternary MRSA cephem derivatives
US6630498B2 (en) * 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
EP1003727A1 (en) 1997-08-07 2000-05-31 Research Corporation Technologies Antibiotic for methicillin resistant bacteria
ES2234139T3 (en) * 1997-08-11 2005-06-16 Alza Corporation Dosage form of an active agent suitable for extended release gastroretention.
US5929219A (en) 1997-09-10 1999-07-27 Abbott Laboratories 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
US20030083733A1 (en) 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US6558699B2 (en) 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US5932710A (en) * 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5919916A (en) 1997-12-01 1999-07-06 Abbott Laboratories 6-O-alkyl derivatives of erythronolide B
US5892008A (en) * 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
DE69819205D1 (en) * 1997-12-22 2003-11-27 Astrazeneca Ab An oral pharmaceutical dosage form based on pulsatile release
US6294526B1 (en) * 1998-02-06 2001-09-25 Alps Pharmaceutical Ind. Co., Ltd. Use of flavone derivatives for induction of β-lactam-sensitivity of MRSA
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6288212B1 (en) 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
KR100377159B1 (en) * 1998-09-09 2003-08-19 한미약품공업 주식회사 Production method of the crystal form of azithromycin 2 as there is no residual solvent clarithromycin
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
DE19845358A1 (en) 1998-10-02 2000-04-06 Roehm Gmbh Coated dosage forms controlled release
US6384081B2 (en) 1998-10-09 2002-05-07 Charles L. Berman Treatment of diseases of the eye characterized by the formation of metalloproteinase
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
CN100444830C (en) 1998-11-02 2008-12-24 伊兰公司,Plc Multiparticulate modified release composition
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
DE19852192C2 (en) * 1998-11-12 2003-04-24 Bayer Ag Active ingredient-containing aromatic copolyester
US6159491A (en) 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
US7127285B2 (en) * 1999-03-12 2006-10-24 Transport Pharmaceuticals Inc. Systems and methods for electrokinetic delivery of a substance
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6187768B1 (en) * 1999-06-01 2001-02-13 Becton, Dickinson And Company Kit for flushing medical devices and method of preparation
US6946458B2 (en) * 1999-07-22 2005-09-20 University Of South Florida N-thiolated beta-lactams: novel antibacterial agents for methicillin-resistant Staphylococcus aureus
WO2001010407A1 (en) 1999-08-06 2001-02-15 Pharmacia & Upjohn Company Intravaginal clindamycin ovule composition
DE19938704C1 (en) * 1999-08-14 2001-10-31 Ivoclar Vivadent Ag A process for the preparation of reaction systems for implantation in the human and animal body as a bone substitute, which contain inter alia calcium and phosphorus
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
KR100322313B1 (en) * 1999-10-21 2002-02-06 민경윤 Method of preparing form ii crystals of clarithromycin and clarithromycin formate used therein
CA2392085A1 (en) * 1999-11-15 2001-05-25 Smithkline Beecham Corporation Carvedilol methanesulfonate
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6627743B1 (en) * 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
US6599884B2 (en) 1999-12-16 2003-07-29 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph IV
ES2236023T3 (en) * 2000-01-11 2005-07-16 Teva Pharmaceutical Industries Ltd. Process for preparing clarithromycin polymorphs.
CA2395974A1 (en) * 2000-01-20 2001-07-26 Suggy S. Chrai Multi-step drug dosage forms
US6284235B1 (en) 2000-02-11 2001-09-04 National Starch And Chemical Company Investment Holding Corporation Bioadhesive composition
EP1267765A4 (en) * 2000-02-24 2008-12-24 Middlebrook Pharmaceuticals In Antibiotic and antifungal compositions
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US7108859B2 (en) 2000-10-13 2006-09-19 Advancis Pharmaceutical Corporation Antineoplastic product, use and formulation thereof
US6663891B2 (en) * 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6623758B2 (en) * 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6669948B2 (en) * 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6627222B2 (en) * 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US6638532B2 (en) * 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US20020004070A1 (en) * 2000-02-24 2002-01-10 Rudnic Edward M. Antineoplastic product, use and formulation thereof
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6632453B2 (en) * 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US7105174B2 (en) 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US6667057B2 (en) * 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6610328B2 (en) * 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6667042B2 (en) * 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
WO2001068662A1 (en) * 2000-03-15 2001-09-20 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form ii crystals
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
CA2407335C (en) 2000-05-03 2010-08-03 Joe D'silva Process and device for producing liquid dosage formulations
US7276252B2 (en) * 2000-05-18 2007-10-02 Massachusetts Institute Of Technology Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
WO2001092288A3 (en) 2000-05-31 2002-06-27 Douglas A Collins Cobalamin compounds useful as antibiotic agents and as imaging agents
KR20030010721A (en) * 2000-06-16 2003-02-05 파마시아 앤드 업존 캄파니 A Thiazine Oxazolidinone
WO2001098317A3 (en) * 2000-06-22 2002-09-26 Brigham & Womens Hospital Alpha-glycosylceramides for treating bacterial and fungal infections
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
EP1301177A2 (en) * 2000-07-10 2003-04-16 Massachusetts Institute Of Technology Method and materials for controlling migration of binder liquid in a powder
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
US6767899B1 (en) 2000-08-29 2004-07-27 Leiner Health Services Corp. Composition and method for treatment of conditions having an inflammatory component
US20020081332A1 (en) 2000-08-29 2002-06-27 Ashok Rampal Controlled release formulation of erythromycin or a derivative thereof
EP1318792B1 (en) * 2000-09-22 2005-01-05 Galephar M/F Sustained release composition containing clarithromycin
US20020103261A1 (en) * 2000-10-06 2002-08-01 Dusan Ninkov Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals
EP1324748A1 (en) 2000-10-10 2003-07-09 Pharmacia & Upjohn Company Topical antibiotic composition for treatment of eye infection
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US7074417B2 (en) 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
CA2432797C (en) * 2000-12-18 2014-02-04 David J. Yang Local regional chemotherapy and radiotherapy using in situ hydrogel
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US20020119168A1 (en) * 2001-02-20 2002-08-29 Rudnic Edward M. Therapeutic agent delivery
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
CA2440641A1 (en) * 2001-03-13 2002-09-19 Anand R. Baichwal Chronotherapeutic dosage forms containing glucocorticosteroid
EP2311440A1 (en) 2001-04-05 2011-04-20 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US6777420B2 (en) * 2001-06-15 2004-08-17 Microbiotix, Inc. Heterocyclic antibacterial compounds
CA2452738C (en) * 2001-07-04 2011-06-14 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2003020736A1 (en) 2001-08-28 2003-03-13 Pharmacia Corporation Crystaline clindamycin free base
US6642276B2 (en) 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP4845340B2 (en) 2001-10-29 2011-12-28 マサチューセッツ インスティテュート オブ テクノロジー System and method for uniaxial compression of an article such as a three-dimensional printed dosage forms
WO2003037244A3 (en) * 2001-10-29 2004-01-22 Therics Inc System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
US20030091627A1 (en) 2001-10-31 2003-05-15 Vinay Sharma Rate-controlled delivery of macrolides
US20030129236A1 (en) 2001-12-20 2003-07-10 Heimlich John M. Multiple pulse extended release formulations of clindamycin
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
CA2477044A1 (en) 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic formulation with gum system
WO2003082241A3 (en) * 2002-04-03 2004-01-08 Ranbaxy Lab Ltd Clarithromycin formulations having improved bioavailability
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
US20040033262A1 (en) * 2002-08-19 2004-02-19 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic
US20040091528A1 (en) 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
CA2520867A1 (en) 2003-04-02 2004-10-21 Colin E. Rowlings Pulsatile transdermally administered antigens and adjuvants
WO2004112711A3 (en) * 2003-06-16 2005-05-19 Andrx Pharmaceuticals Llc Oral extended-release composition
US8313776B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2533358C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (en) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotics, their use and creating
WO2005016278A3 (en) * 2003-08-12 2005-05-19 Advancis Pharmaceuticals Corp Antibiotic product, use and formulation thereof
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
US7455840B2 (en) 2003-11-19 2008-11-25 The Scripps Research Institute Compositions and methods to reduce mutagenesis
US7247634B2 (en) 2004-01-13 2007-07-24 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes
EP1723150A1 (en) * 2004-01-13 2006-11-22 Cumbre Pharmaceuticals Inc. Rifamycin imino derivatives effective against drug-resistant microbes
US7256187B2 (en) * 2004-03-10 2007-08-14 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7265107B2 (en) * 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7250413B2 (en) 2004-04-26 2007-07-31 Cumbre Pharmaceuticals Inc. C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
US7202246B2 (en) 2004-06-09 2007-04-10 Cumbre Pharmaceuticals Inc. Spiro-rifamycin derivatives targeting RNA polymerase
DE602005013671D1 (en) * 2004-07-22 2009-05-14 Cumbre Pharmaceuticals Inc rifamycin derivatives, their preparation and pharmaceutical compositions (r / s)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062229A1 (en) * 2000-02-24 2001-08-30 Advanced Pharma, Inc. Therapeutic product, use and formulation thereof
WO2004012704A1 (en) * 2002-08-02 2004-02-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2004103311A2 (en) * 2003-05-19 2004-12-02 Advancis Pharmaceuticals Corporation Antibiotic composition

Also Published As

Publication number Publication date Type
WO2005023184A3 (en) 2005-09-22 application
US20050048114A1 (en) 2005-03-03 application
US8246996B2 (en) 2012-08-21 grant
WO2005023184A2 (en) 2005-03-17 application
EP1658034A2 (en) 2006-05-24 application
CA2535780A1 (en) 2005-03-17 application
JP5686494B2 (en) 2015-03-18 grant
JP2007504141A (en) 2007-03-01 application

Similar Documents

Publication Publication Date Title
GB2386116B (en) Product dispensers
GB2406791B (en) Minoxidil pharmaceutical foam formulation
GB0315450D0 (en) Biological products
GB0315457D0 (en) Biological products
GB0329825D0 (en) Biological products
GB0319588D0 (en) Biological products
GB0319287D0 (en) Bottle
GB0326104D0 (en) Bottle
GB0315397D0 (en) Bottle
GB0223779D0 (en) Use and process
GB0218501D0 (en) Deformable article
GB0305416D0 (en) Sheet or the like, for topical therapeutic use, and process for its preparation
GB0210710D0 (en) Retaining article
GB0200263D0 (en) Novel product
GB0205277D0 (en) Azetidinium-functionalised polymer and compositions containing the same
GB0323744D0 (en) Nappy
GB0323942D0 (en) Field emitters and devices
GB0225876D0 (en) Use
GB0213878D0 (en) Use
GB0229442D0 (en) Use
GB0229581D0 (en) Use
GB0222408D0 (en) Use
GB0214802D0 (en) Use
GB0230343D0 (en) Use
GB0206203D0 (en) Use

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

17P Request for examination filed

Effective date: 20060215

RIC1 Classification (correction)

Ipc: A61K 9/14 20060101AFI20060427BHEP

Ipc: A61K 9/24 20060101ALI20060427BHEP

Ipc: A61K 9/54 20060101ALI20060427BHEP

Ipc: A61K 9/20 20060101ALI20060427BHEP

Ipc: A61K 9/52 20060101ALI20060427BHEP

DAX Request for extension of the european patent (to any country) deleted
RAP1 Transfer of rights of an ep published application

Owner name: MIDDLEBROOK PHARMACEUTICALS, INC.

RAP1 Transfer of rights of an ep published application

Owner name: MIDDLEBROOK PHARMACEUTICALS, INC.

A4 Despatch of supplementary search report

Effective date: 20110524

RIC1 Classification (correction)

Ipc: A61K 9/20 20060101ALI20110518BHEP

Ipc: A61K 9/54 20060101ALI20110518BHEP

Ipc: A61K 31/00 20060101ALI20110518BHEP

Ipc: A61K 9/50 20060101ALI20110518BHEP

Ipc: A61K 9/52 20060101ALI20110518BHEP

Ipc: A61K 9/24 20060101ALI20110518BHEP

Ipc: A61K 9/14 20060101AFI20060427BHEP

RAP1 Transfer of rights of an ep published application

Owner name: SHIONOGI INC.

17Q First examination report

Effective date: 20120425

18D Deemed to be withdrawn

Effective date: 20121106